Skip to main content
Ascletis Pharma Inc. logo

Ascletis Pharma Inc. — Investor Relations & Filings

Ticker · 1672 ISIN · KYG0520K1094 LEI · 254900SKEFCO9I3GPL05 HKEX Manufacturing
Open in API
Filings indexed 1,469 across all filing types
Latest filing 2025-08-15 Report Publication Anno…
Country KY Cayman Islands
Listing HKEX 1672

About Ascletis Pharma Inc.

http://www.ascletis.com

Ascletis Pharma Inc. is a fully integrated, R&D driven biotechnology company dedicated to the development and commercialization of potential best-in-class and first-in-class therapeutics. The company covers the entire value chain from discovery to sales. Ascletis primarily focuses on metabolic diseases, including chronic weight management, utilizing proprietary platforms such as Artificial Intelligence-assisted Structure-Based Drug Discovery (AISBDD), Ultra-Long-Acting Platform (ULAP), and Peptide Oral Transport ENhancement Technology (POTENT). Key pipeline candidates include ASC30 (oral/subcutaneous GLP-1R agonist), ASC35 (GLP-1R/GIPR dual agonist), ASC36 (amylin receptor agonist), and ASC37 (GLP-1R/GIPR/GCGR triple agonist). The company also maintains active programs in viral diseases, NASH/PBC, and oncology.

Recent filings

Filing Released Lang Actions
DATE OF BOARD MEETING
Report Publication Announcement Classification · 1% confidence The document is a short announcement by the Company under Hong Kong Exchange rules, notifying investors of the date of a Board meeting to approve and release the unaudited interim results and consider an interim dividend. It does not itself contain financial results or auditor opinions; rather, it is announcing the timing of the report release. This fits the definition of a Report Publication Announcement (RPA), as it informs shareholders of when the report will be approved and published.
2025-08-15 English
INTERIM RESULTS ANNOUNCEMENT FOR THE SIX MONTHS ENDED JUNE 30, 2025
Interim / Quarterly Report Classification · 1% confidence The document is an 'Interim Results Announcement' for Ascletis Pharma Inc. for the six months ended June 30, 2025. It contains unaudited consolidated financial statements, financial highlights, and a detailed Management Discussion and Analysis (MDA) section covering business operations and pipeline progress. As it provides comprehensive financial data and analysis for a period shorter than a full fiscal year, it is classified as an Interim/Quarterly Report. H2 2025
2025-08-15 English
VOLUNTARY ANNOUNCEMENT - ASCLETIS ANNOUNCES ASC47, A MUSCLE-PRESERVING WEIGHT LOSS DRUG CANDIDATE FOR TREATMENT OF OBESITY, DEMONSTRATED GREATER EFFICACY WITH TIRZEPATIDE THAN SEMAGLUTIDE IN A PRECLIN
Regulatory Filings Classification · 1% confidence The document is a voluntary announcement by Ascletis Pharma on the Stock Exchange of Hong Kong presenting preclinical efficacy data for a drug candidate. It is not a financial report (e.g., Annual Report, Interim Report), not an earnings release, not a management change notice, no capital or financing details, no dividend declaration, no AGM materials, no legal or M&A matter. It is essentially a press/news announcement of scientific results and does not fit any of the specific categories, making it a general regulatory announcement that falls under the fallback category “Regulatory Filings (RNS).”
2025-08-13 English
VOLUNTARY ANNOUNCEMENT - ASCLETIS COMPLETES ENROLLMENT IN U.S. PHASE IIA STUDY FOR ITS SMALL MOLECULE ORAL GLP-1R AGONIST, ASC30, IN PARTICIPANTS WITH OBESITY OR OVERWEIGHT
Regulatory Filings Classification · 1% confidence The document is a voluntary corporate announcement regarding the completion of enrollment in a clinical Phase IIa study. It does not present financial results, governance changes, dividends, or any of the other defined categories such as earnings releases, board changes, capital transactions, or M&A. It is a general regulatory announcement made to keep investors informed. Therefore, it falls into the fallback category 'Regulatory Filings' (RNS).
2025-08-05 English
Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 July 2025
Regulatory Filings Classification · 1% confidence The document is a standardized HKEX listing‐rule form (FF301) titled “Monthly Return for Equity Issuer…on Movements in Securities” covering authorized/issued share capital, share options, repurchases, etc. It is a routine periodic regulatory report filed under Chapter 19B, not an annual or interim report, earnings release, proxy, or standalone share‐issue notice. It does not announce a specific new capital change event but provides a monthly summary return as required by the exchange. Therefore it is best classified as a general regulatory filing (RNS).
2025-08-04 English
Monthly Return of Equity Issuer on movements in Securities for the month ended 31 July 2025
Regulatory Filings Classification · 1% confidence The document is a monthly return (Form FF301) filed with the Hong Kong Stock Exchange under Chapter 19B listing rules, detailing routine movements in authorised share capital, issued shares, treasury shares and share option schemes. It is not an earnings release, annual or interim report, nor is it a one-off share issuance announcement under our "Share Issue/Capital Change" category—it is a recurring regulatory submission. There is no specific category for these monthly share-movement returns, so it falls under the general "Regulatory Filings" (RNS) fallback category.
2025-08-01 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.